~~<i id='2BE5D575FC'><strike id='2BE5D575FC'><tt id='2BE5D575FC'><pre id='2BE5D575FC'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-10-06 07:37:11 Page View：421

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer, immunology, HIV research ensnared in fetal tissue politics
Next article： New air purifier tech could be key to improving indoor air quality

comprehensive

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

How a small hospital in rural Puerto Rico survived Hurricane Maria

AfterHurricaneMaria,mostresidentsofruralPuertoRicowerewithoutelectricityandcutofffromhealthcare.InMo

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

Chemotherapy before breast cancer surgery might fuel metastasis

Abreastcancertumorimagedwithatechniquethathighlightsaspectsofitsmicroenvironment.NationalCancerInsti